This website provides only an introduction to the PASADENA study. To learn more, the study medical team can answer your questions.
The PASADENA study will assess the safety and efficacy of prasinezumab.
Prasinezumab (also known as RG7935/PRX002) is an investigational molecule being developed for people with Parkinson’s disease. The treatment is called ‘investigational’ as it is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or similar government agencies abroad.
A number of medical centers around the world are participating in the PASADENA study.
Some of these centers participated in an initial study of the PASADENA investigational treatment. The initial study focused on the safety of the investigational treatment.
The investigational treatment was given to people with PD, and to a small group of people who do not have PD.
Your study doctor will monitor and follow your treatment throughout the clinical study. You can call your study doctor with any concerns you might have about the care you receive during the study.
What is a good place to start? First, find out if you are eligible to join the PASADENA study. This is decided on medical grounds. You first review your precise medical diagnosis and physical condition with the medical team. They then make an evaluation for you.
It is important to complete this evaluation as soon as possible. The PASADENA study is for people with early stage PD.
To participate in the study, you need to have been diagnosed with PD in the past two years. You should not have received dopaminergic therapy for more than a total of 60 days.
The Hoehn & Yahr (H&Y) scale is used to determine the stage of PD. Early stage clinical PD corresponds to stages 1 and 2 on the H&Y scale. A H&Y score of 1 is made when movement symptoms are confined to one side. A score of 2 is made when symptoms affect both sides of the body, and when the sense of balance is not yet impacted.
If you are eligible for a place on the PASADENA study, you will be invited to join the study by the study medical team. This team provides medical care to participants of the clinical study. The entire team is specialized in the treatment of PD.
A number of new and sensitive methods are being used to measure the clinical impact of the investigational treatment. Some of those measurements are made with smartphones and wrist-worn wearable devices.
These measurements provide a more sensitive assessment of PD symptoms. They enable us to understand how symptoms change continuously, on a day-to-day basis.
Scientists believe that making continuous and accurate assessment of PD symptoms is critical for our understanding of PD and the development of novel treatments.
Detailed aspects of the study will be presented to you at the medical center conducting the PASADENA study.
Clinical studies are conducted in medical centers such as Hospitals and specialized clinics. You will receive the regular protections offered to all patients at these medical centers.
In addition to these protections, participants in clinical studies are monitored closely by independent experts. These experts follow the study from beginning to end.
Perhaps your own doctor has mentioned the possibility of participating in a clinical study for PD? We encourage you to discuss this option with your doctor and with others who can support you to make decisions about your care and treatment.
Thank you for stopping by. Visit the website again for updates about the PASADENA study.